newsfilter
← Latest News
GlobeNewswire·

Hemab Therapeutics to Report Third Quarter 2026 Financial Results and Provide a Corporate Update on November 10, 2026

  • Hemab Therapeutics (NASDAQ: COAG) will host a conference call on Tuesday, November 10, 2026, at 8:00 a.m. ET.
  • The call aims to discuss financial results & provide a corporate update for the third quarter ended September 30, 2026.
  • Registration for the webcast is available via the company's investor page or a direct link.
  • Analysts can join the Q&A session using a specific link provided by the company.
  • A replay of the webcast will be posted approximately two hours after the call & remain available for 90 days.
  • Participants are advised to join the call 15 minutes prior to the scheduled start time.
  • Hemab is developing sutacimig (HMB-001) for Glanzmann thrombasthenia & Factor VII deficiency prophylaxis.
  • The company is also developing HMB-002 for Von Willebrand Disease prophylaxis & HMB-003 for heavy menstrual bleeding.